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ABSTRACT  31 
The use of donor human breast milk instead of formula reduces the risk of necrotising enterocolitis 32 
(NEC) in preterm infants when their mother͛s own milk is insufficient.  Use of donor milk is limited by 33 
the cost of establishing a milk bank and a lack of donors, but the optimal rationing of limited donor 34 
milk is unclear. This paper uses an economic model to explore how a limited donor milk supply 35 
should be allocated across very low birthweight infants in South Africa considering two outcomes: 36 
maximising lives saved and minimising costs. 37 
We developed a probabilistic cohort Markov decision model with 10,000 infants across four 38 
birthweight groups.  We evaluated allocation scenarios in which infants in each group could be 39 
exclusively formula-fed or fed donor milk for 14 or 28 days and thereafter formula until death or 40 
discharge.   41 
Prioritising infants in the lowest birthweight groups would save the most lives, while prioritising 42 
infants in the highest birthweight groups would result in the highest cost savings. All allocation 43 
scenarios would be considered very cost-effective in South Africa compared to the use of formula; 44 
the ͚worst case͛ was $619 per Disability Adjusted Life Year averted. 45 
There is a compelling argument to increase the supply of donor milk in middle income countries. Our 46 
analysis could be extended by taking a longer-term perspective, using data from more than one 47 
country and exploring the use of donor milk as an adjunct to mother͛s own milk, rather than a pure 48 
substitute for it.  49 
 50 
Key words: donor human breast milk, very low birthweight, necrotising enterocolitis, economic 51 
evaluation, rationing 52 
  53 
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INTRODUCTION 54 
 55 
In the absence or limited supply of breastmilk from a preterm or very low birthweight (VLBW) 56 
infant͛s biological mother, leading health organisations recommend the use of donor human milk as 57 
the first alternative (Arslanoglu et al., 2013; Eidelman et al., 2012; UNICEF, 1995).  This 58 
recommendation results from evidence that donor milk reduces the incidence and severity of 59 
necrotising entercolitis (NEC) (Arslanoglu et al., 2013; Quigley & McGuire, 2014).  Given appropriate 60 
safeguards including the screening of potential donors (NICE, 2010), there are relatively few safety 61 
concerns regarding the use of donor milk and a recent systematic review did not find evidence that 62 
donor milk crowded out the provision of a mother͛s own milk (Williams, Nair, Simpson, & Embleton, 63 
2016).  However, although there are no definitive bottom-up costings of supplying donor milk, it is 64 
clearly more expensive than using formula when a mother͛s own milk is not available (Jegier, Meier, 65 
Engstrom, & McBride, 2010) and thus its cost-effectiveness needs to be considered when deciding 66 
whether – and if so, to whom - it should be provided. This is a key issue in low- and middle- income 67 
countries where resources for healthcare are particularly scarce (WHO Commission on 68 
Macroeconomics and Health, 2001).    69 
 70 
A previous study examined the cost-effectiveness of donor milk as an adjunct to mother͛s own milk 71 
and alongside an intervention to increase breastfeeding rates (Renfrew et al., 2009). However a 72 
systematic review of the cost-effectiveness of exclusive donor milk feeding compared with exclusive 73 
formula milk feeding (Buckle & Taylor, 2017) identified only three studies in two papers offering any 74 
form of economic evaluation (Arnold, 2002; Wight, 2001).  All of these were cost-minimisation 75 
analyses and, while all reported likely cost savings from the use of donor milk, none is sufficiently 76 
robust for decision-making.  For example, all three studies assumed that donor milk would be as 77 
effective as mother͛s own milk in preventing NEC and none included the healthcare costs arising 78 
when an infant who would have died from NEC survives. None of the studies included a sensitivity 79 
analysis.   80 
 81 
This lack of good quality specific evidence of cost-effectiveness limits attempts to increase the 82 
resources required to develop and run milk banks.  Supply may also be limited by a lack of donors 83 
and hence there is often insufficient donor milk to meet demand (Medo, 2013; Miracle, Szucs, Torke, 84 
& Helft, 2011; Tully, 2002).  Where there is excess demand, it is necessary to prioritise allocation.  85 
The prioritisation criteria promoted by the Human Milk Banking Association of North America 86 
incorporate recipient factors, maternal factors and time factors, affording the highest priority to 87 
preterm infants (Tully, 2002).  The criteria are viewed as a means of promoting an ethical approach 88 
to allocation (Miracle et al., 2011; Tully, 2002), but are not based on a formal analysis of costs versus 89 
benefits (British Association of Perinatal Medicine, 2015). Moreover, they do not explicate how 90 
decisions should be made within specific groups so it is not surprising that both UK and US surveys of 91 
neonatal units have found significant variation in the criteria applied in practice (Hagadorn, 92 
Brownell, Lussier, Parker, & Herson, 2016; Zipitis, Ward, & Bajaj, 2015). 93 
 94 
This paper seeks to address the current lack of a full economic model and provide recommendations 95 
as to how donor milk should be allocated amongst VLBW infants according to birthweight. We 96 
consider the effect of different approaches to prioritisation on two NEC-related outcomes resulting 97 
from the use of donor milk as an alternative to formula: the number of lives saved and short-term 98 
costs/savings to the health service. 99 
 100 
METHODS 101 
 102 
This study follows the Consolidated Health Economic Evaluation Reporting Standards (Husereau et 103 
al., 2013). 104 
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 105 
Setting and location 106 
The setting for the model is neonatal units in South Africa that need to decide how to allocate donor 107 
milk amongst VLBW infants (<1,500g). We selected a middle-income country focus because of the 108 
increased pressure on healthcare resources in comparison with high-income countries and better 109 
availability of data in comparison with low-income countries. Furthermore, most of the world͛s 110 
population lives in middle-income countries. We have used clinical data from Groote Schuur Hospital 111 
in Cape Town to help parameterise our model as outlined below.  Groote Schuur is a state funded 112 
Level 3 hospital. The neonatal unit has 75 beds in total, and admits approximately 2,000 babies every 113 
Ǉear, Ϯ5% of ǁhoŵ haǀe a birthǁeight ≤ϭ5ϬϬg. ApproǆiŵatelǇ ϭϬ% of adŵissioŶs are ELBW.  The 20 114 
bedded NICU is able to provide non-invasive and invasive ventilation including High Frequency 115 
Oscillation and Nitric Oxide as well as offer Therapeutic Hypothermia.  The 55 remaining beds are 116 
high care and general neonatal beds. 117 
 118 
Study perspective and duration 119 
We adopted a health services perspective, including the costs of neonatal care up to the point of 120 
death or initial discharge (maximum 14 weeks).  In the model, events occur at the end of each week, 121 
although milk volumes are calculated on a daily basis.  Costs arising to parents and society and long-122 
term health service costs are excluded.  Costs are shown in 2015 US Dollars at Purchasing Power 123 
Parity (PPP),  inflated to 2015 values using local indices and converted to PPP using the World Bank 124 
exchange rates for 2015 where required (World Bank, 2015b). 125 
 126 
Target population and subgroups 127 
The target population is VLBW infants (<1,500g), the target population for provision of donor milk in 128 
the preterm feeding policy for the Western Cape province of South Africa.  In the model a cohort of 129 
10,000 VLBW infants is considered, which represents around one-third of the annual number of 130 
VLBW infants across South Africa.  VLBW is a proxy for preterm infants, since almost all data used to 131 
parameterise the model are from sources based on birthweight groups rather than gestational age.  132 
Four groups based on birthweight are used (500-750g, 751-1,000g, 1,001-1,250g and 1,251-1,500g), 133 
determined by the predominant stratification in the literature and based on 2012/13 Perinatal 134 
Problem Identification Program (PPIP) data aggregated across Western Cape and Mpumulanga 135 
(Pattinson & Rhoda, 2014). These data only present two VLBW categories, 500-999g and 1,000-136 
1,499g, with 42.7% of VLBW infants in the 500-999g category and 57.3% in the 1,000-1,499g 137 
category.  To provide the most realistic incrments between groups, we assumed that 46.4% of each 138 
category would be in the lower of our two groups and 53.6% in the upper (Table 1).  The uncertainty 139 
in this distribution is considered in the probabilistic sensitivity analysis using a Dirichlet distribution 140 
(parameterised using the Pattinson & Rhoda data as described above) as recommended for 141 
multinomial data (Briggs et al., 2006) because the proportion in each group affects the volume of 142 
donor milk required for each allocation scenario.  143 
 144 
Comparators 145 
The study considers VLBW infants for whom no maternal milk can be provided (e.g. through 146 
maternal death, absence or specific contraindications).  Such infants can be provided with either 147 
donor milk (intervention) or formula milk (control). Neither type of milk is fortified (a recent review 148 
did not find a statistically significant effect of fortification on outcomes (Brown, Embleton, Harding, 149 
& McGuire, 2016)) and no probiotics are added.  Although non-maternal milk is often used as an 150 
adjunct to support mothers while their own milk supply is being established (British Association of 151 
Perinatal Medicine, 2015), we considered only donor or formula milk for the model given 152 
the lack of evidence on the effectiveness of mixed feeding on reducing the risk of NEC.  153 
 154 
Time horizon – duration of donor milk feeding 155 
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For the lowest three birthweight groups (<1,251g), exclusive donor milk could be given for either 14 156 
or 28 days (or until diagnosis of NEC or death, whichever comes soonest).  However, the highest 157 
birthweight group (1,251-1,500g), exclusive donor milk could be given for 14 days or until diagnosis 158 
of NEC or death.  These two time periods are often cited as critical for NEC risk (British Association of 159 
Perinatal Medicine, 2015; Yee et al., 2012).  However, for the highest birthweight group, 14 days was 160 
used as the only option since an infant in this group surviving NEC-free would be expected to be 161 
discharged at 21 days.  For the period following diagnosis of NEC or after 14/28 days, the infant 162 
would be given exclusive formula milk until death or discharge. Although donor milk may be used in 163 
practice to support the gut following diagnosis of NEC (British Association of Perinatal Medicine, 164 
2015), we did not consider this here as our outcome measures only include the incidence and 165 
severity of NEC. 166 
 167 
Donor milk allocation scenarios considered 168 
Given the four birthweight groups and three durations of donor milk feeding as described above, 169 
there are 53 possible donor milk allocation scenarios, as listed in Appendix table 1. These scenarios 170 
have been split into eight donor milk availability groups according to the total volume of donor milk 171 
required per 10,000 VLBW infants: <5,000L, <10,000L, <15,000L, <20,000L, <25,000L, <30,000L, 172 
<35,000L and 35,000L.   173 
 174 
Choice of health outcomes 175 
The only condition included in the model is NEC, due to the lack of evidence regarding the effect of 176 
donor milk on other outcomes (Arslanoglu et al., 2013).  Donor milk has been shown to reduce the 177 
risk of NEC (Quigley & McGuire, 2014) and breast milk has been shown to reduce its severity 178 
(Guthrie et al., 2003).  NEC generally has two severity categories: medical and surgical; infants 179 
requiring surgery are generally sicker and have a poorer prognosis (Lin & Stoll, 2006).  However for 180 
some infants (those with a particularly poor prognosis) only palliative care is provided.  The effect of 181 
using donor milk rather than formula is estimated in terms of lives saved; the effect on morbidity of 182 
those who survive is excluded. 183 
 184 
Risk of NEC with formula milk 185 
Data from a large US-based retrospective cohort study (Fitzgibbons et al., 2009) are used to estimate 186 
the baseline risk of NEC in each birthweight group.  The estimates are for all methods of feeding 187 
combined, so underestimate the risk for exclusive formula feeding, but we were unable to find a 188 
source that provided risks by birthweight and type of feeding.  The risk for each group is included in 189 
the probabilistic sensitivity analysis (Table 1) using a Beta distribution as recommended for binomial 190 
data (Briggs et al., 2006), parameterised using the results of Fitzgibbons et al.͛s study.   191 
 192 
Measurement of effectiveness 193 
The effect of donor milk feeding compared with formula feeding on the incidence of NEC (relative 194 
risk 0.36, 95% CI 0.18 to 0.71) is taken from the Cochrane Review by Quigley and McGuire (Quigley & 195 
McGuire, 2014).  The estimate of the effect of receiving breast milk on the risk of surgical NEC (as 196 
opposed to medical NEC) is taken from a retrospective cohort study in the US reported by Guthrie 197 
and colleagues (Guthrie et al., 2003).  The odds ratio reported in the paper (0.60, 95% CI 0.40 to 198 
1.00) was converted into a relative risk using the method of Grant (Grant, 2014). Both of these 199 
relative risks and the uncertainty with which they are estimated by Quigley & McGuire and by 200 
Guthrie et al. are included in the probabilistic sensitivity analysis using log normal distributions, as 201 
recommended by Briggs et al., 2006.  Where an infant was ͚saved͛ from surgical NEC through the use 202 
of donor milk, they were assumed to receive medical management and survive.  Given the absence 203 
of emprical evidence, we assume the effect of donor milk on both the risk and severity of NEC is the 204 
same regardless of birthweight. 205 
 206 
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NEC timing, severity and mortality by birthweight group 207 
The distribution of timing of onset of NEC, severity and mortality of NEC cases is shown by 208 
birthweight group in Appendix table 2.  These values are based on a review of NEC cases at the 209 
Groote Schuur Hospital and published evidence from Canada of an inverse relationship between 210 
birthweight and timing of onset (Yee et al., 2012).  We assume that the severity and mortality of NEC 211 
cases is independent of the timing of onset.  Where donor milk is given for 14 days, we assume that 212 
the risk and severity of NEC up until that point would be reduced, but that there would be no 213 
enduring effect of donor milk once it is replaced with formula. 214 
 215 
Non-NEC mortality 216 
Using neonatal mortality data from the Groote Schuur Hospital, we assume that a proportion of 217 
infants in each birthweight group die from other causes at the end of the first week of life (Table 1).  218 
Until the point of non-NEC mortality, all infants are cared for in the neonatal intensive care unit 219 
(NICU). 220 
 221 
Milk volume  222 
Feeding volumes are estimated based on the mean birthweight of an infant in each of the four 223 
birthweight groups.  The means are estimated using a right-angled triangular distribution for each 224 
birthweight group (Table 1).  Our approach to calculating milk volume is based on the policy 225 
implented at Groote Schuur Hospital as follows: 226 
 Enteral feeding begins on day 1 and progresses as shown in Appendix table 3 until infants are 227 
receiving 216 ml/kg/day (based on the findings in the Cochrane Review by Morgan and 228 
colleagues (Morgan, Young, & McGuire, 2015)), regardless of type of milk received.   229 
 Infants lose 10% of their birthweight in week 1, which is regained by the end of week 2. 230 
 Subsequent weight gain occurs at the rate of 14g/kg/day, based on South African data (Lango, 231 
Horn, & Harrison, 2013), regardless of type of milk received. 232 
 Infants stop receiving milk on diagnosis of NEC and are intially fed parenterally.  Enteral feeding 233 
(using formula) resumes seven days after onset for those who survive medical NEC and 21 days 234 
after onset for those who survive surgical NEC, assuming, in the absence of empirical evidence, 235 
NEC does not influence infant weight.  Infants with palliative NEC are fed parenterally for two 236 
days before death. 237 
The volume of milk required varies by birthweight group, incidence and type of NEC and by timing of 238 
onset of NEC (Appendix table 4). 239 
 240 
Milk costs 241 
We use costs of USD 0.0529/ml for formula milk and USD 0.1371/ml for donor milk.  The cost of 242 
formula milk was provided through personal communication with the Chief Dietician at RK Khan 243 
Hospital in KwaZulu Natal, South Africa based on ready-to-feed bottles of Similac Special Care (ZAR 244 
68.9 for 236ml in 2015). We did not adjust for any wastage if not all of a bottle was used.  The cost of 245 
donor milk was provided through personal communication with the Milk Matters milk bank in Cape 246 
Town, South Africa (ZAR 75.7 for 100ml in 2015).  Donors are not paid for their milk.  Our systematic 247 
review (Buckle & Taylor, 2017) has found eight estimates of the cost of donor milk, all from high-248 
income countries. The lowest costs were from Scandinavia (USD 0.08-0.10/ml); costs from US 249 
sources ranged from USD 0.11 to 0.15/ml; and the highest costs were from the UK (USD 0.21 to 250 
0.51/ml, all at 2015 PPP). However there was variation as to what cost components were included in 251 
these estimates making direct comparisons unreliable. 252 
 253 
Length of stay 254 
Appendix table 5 shows the number of days in each type of neonatal care (NICU, High care and 255 
Normal care) required by outcome and birthweight group, based on clinical data from Groote Schuur 256 
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Hospital.  The total length of stay for infants acquiring NEC but not surviving varies according to the 257 
timing of onset of NEC (as shown in Appendix table 6). 258 
 259 
Daily cost of care 260 
As direct estimates of daily care costs were not available for South Africa (only charges billed to 261 
parents/insurers), we use two approaches to costing (Table 1): 262 
 UK costs for each type of neonatal care are taken from the Department of Health͛s 2014 schedule 263 
of reference costs (Department of Health, 2014), which include the time of all healthcare and 264 
other staff and any medicines required.  2014 values were increased by 1% to adjust for inflation 265 
to 2015 values, as recommended (PSSRU, 2014) given the unavailability of 2015 values at the 266 
time of analysis.   267 
 UK costs are adjusted to reflect the relative cost of care in South Africa based on data from the 268 
2015 Comparative Price Report produced by the International Federation of Health Plans 269 
(International Federation of Health Plans, 2015).  The (private healthcare) costs of ten different 270 
procedures in both the UK and South Africa were included in this report, with a mean costs ratio 271 
of 0.485 (i.e. costs in South Africa are 48.5% of those in the UK). 272 
  273 
Other health service resource use and costs  274 
Infants with surgical NEC require neonatal surgery for their condition.  Based on clinical input from 275 
Groote Schuur Hospital, infants who die are assumed to have one operation and those who survive 276 
have three.  The costs of these procedures are estimated using the same two approaches as for the 277 
daily cost of care (Table 1), based on UK reference costs for a major neonatal diagnosis, non-elective 278 
inpatients, short stay as used in a previous study (Renfrew et al., 2009). Many infants in South Africa 279 
receive neonatal care at a hospital which cannot provide such surgery, so we assume, based on local 280 
clinical advice, return ambulance transfers are required for 80% of infants, at standard South African 281 
rates (Republic of South Africa, 2016).  Finally, all infants acquiring NEC require parenteral nutrition 282 
while in the neonatal intensive care unit.  Fixed and daily costs of parenteral nutrition were obtained 283 
from Groote Schuur Hospital (Table 1). 284 
 285 
Incremental cost of treating NEC 286 
The estimated incremental cost of treating NEC (including parenteral nutrition but excluding milk 287 
costs) per infant is shown in Appendix table 6 by type of NEC, birthweight group and timing of onset.  288 
The comparator is infants who do not acquire NEC and who survive until discharge.  For those who 289 
survive NEC, our estimates of the mean incremental cost of initial hospital treatment per infant are 290 
USD 26,000 for medical NEC and 67,500 for surgical NEC (2015 values at PPP).   291 
 292 
Discount rate 293 
As the maximum length of stay considered in the model is 98 days, no discounting of costs is 294 
required.  The primary health outcome considered is lives saved which does not require discounting. 295 
 296 
Choice of model 297 
We developed a cohort simulation model with each cohort including 10,000 VLBW infants who 298 
cannot receive any of their own mother͛s milk.  An example of the corresponding decision tree for 299 
the 1,251-,1500g birthweight group is shown in Figure 1.  The model was developed using Excel 2010 300 
and is available on request; a user can input their own unit costs and this will automatically change 301 
the results (keeping the clinical parameters constant).  Using random draws from the relevant 302 
probability distributions, we simulated 1,000 cohorts to generate 95% credible intervals to reflect 303 
the uncertainty of the input parameters and repeated this process for both UK and South African 304 
cost estimates.  The short-term nature of the model and its relative simplicity meant that a cohort 305 
simulation was preferred to a Markov model or an individual-level simulation. 306 
 307 
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Analytical methods 308 
For each of the 53 donor milk allocation scenarios, we estimated the number of lives saved and 309 
incremental cost (or saving) associated with the use of donor milk in that scenario, compared to 310 
formula milk, using the mean values from the 1,000 simulated cohorts. Within each donor milk 311 
availability group, we identified the scenario that maximised the number of lives saved and 312 
minimised the incremental cost. We calculated the probability that these identified scenarios were 313 
optimal (i.e. the proportion of the 1,000 simulations in which that scenario maximised lives 314 
saved/minimised costs).  For each allocation scenario, we also estimated the litres of donor milk 315 
needed to save one life and the net financial cost or saving associated with the use of one litre of 316 
donor milk. We estimated the cost-effectiveness of the use of donor milk in terms of the cost per 317 
Disability Adjusted Life Year (DALY) averted, valuing one neonatal life saved at 21.9 DALYs (Sabin et 318 
al., 2012).  We started with the least cost-effective allocation scenario, comparing the cost per DALY 319 
averted with the WHO-CHOICE threshold of one GDP per capita (USD 13,165 in South Africa (World 320 
Bank, 2015a)) for a ͞very cost-effective͟ intervention (Tan-Torres Edejer, 2003).   321 
 322 
Ethics 323 
No primary data were collected for the purpose of conducting this study; thus although aggregated, 324 
anonymised data from Groote Schuur Hospital in Cape Town were used to provide some parameter 325 
values, ethical approval was considered not to be required. 326 
 327 
RESULTS 328 
 329 
Parameter values 330 
Table 1 summarises the parameters included in the model as detailed in the methods section. 331 
 332 
Maximising lives saved with a given availability of donor milk 333 
Table 2 shows the optimal allocation of donor milk within each donor milk availability grouping in 334 
terms of maximising the number of lives saved per 10,000 VLBW infants.  Apart from the <25,000L 335 
availability grouping, there is a high (>90%) probability that the scenario identified within each 336 
grouping is optimal. For the <25,000L availability grouping, a second allocation scenario was almost 337 
as effective.  The two scenarios only differed by reallocating the 15-28 days of donor milk for the 338 
751-1,000g birthweight group to 0-14 days for the 1,251-1,500g birthweight group, with the slightly 339 
less effective option just making it into the <25,000L availability grouping. When the supply of donor 340 
milk is limited, lives saved can be maximised by following two general rules: (1) prioritise infants in 341 
the two lowest birthweight groups (<1,000g) and (2) give donor milk for 14 days to two adjacent 342 
birthweight groups rather than for 28 days to only those in the lower of those two groups.   343 
  344 
Minimising incremental costs with a given availability of donor milk 345 
Table 3 shows the optimal allocation of donor milk within each donor milk availability group in terms 346 
of minimising the incremental costs to the health service per 10,000 VLBW infants, for UK and South 347 
African cost estimates.  For both costing methods, the optimal allocation scenario with at least 348 
5,000L of donor milk available is cost saving. With between 5,000 and 15,000L of donor milk, the 349 
optimal allocation scenario is to feed infants in the 1,001-1,250g birthweight group with donor milk 350 
for 14 days under both UK and South African costs. This remains the optimal allocation scenario 351 
using South African costs even when there is more than 15,000L of donor milk available per 10,000 352 
VLBW infants. Under UK costs with more than 15,000L of donor milk available, the optimal allocation 353 
scenario is to give donor milk to all infants >1,000g for 14 days. As with maximising lives saved, there 354 
is a high probability that the scenario identified within each availability grouping is optimal (>80%).  355 
 356 
Maximising the health returns to donor milk consumption 357 
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Across all levels of donor milk availability, the health returns associated with every 1L of donor milk 358 
are maximised when only infants in the 500-750g birthweight group are fed with donor milk for 14 359 
days.  In this scenario, a mean of 24 litres of donor milk is required to save one life (1L therefore 360 
saves 0.04 lives) and 48 infants need to be fed with donor milk in order to save one life.  361 
 362 
Maximising the economic returns to donor milk consumption 363 
With the exception of the <5,000L donor milk availability grouping, the economic returns (cost 364 
savings) associated with every 1L of donor milk are maximised when the 1,001-1,250g birthweight 365 
group are fed with donor milk for 14 days.  In this scenario the net saving resulting from the use of 366 
every 1L of donor milk is USD 115 with UK costs or USD 25 with South African costs. 367 
 368 
Making fair and efficient allocation decisions 369 
In the worst-case allocation scenario in terms of cost-effectiveness (only giving donor milk to infants 370 
in the 500-750g birthweight group for 14 days), the incremental cost-effectiveness ratios were USD 371 
619 per DALY averted using UK costs or USD 259 using South African costs. These ratios would be 372 
considered ͞very cost-effective͟ in South Africa based on the WHO-CHOICE threshold of one GDP 373 
per capita per DALY averted (Tan-Torres Edejer, 2003). Thus all other allocation scenarios would be 374 
͞very cost-effective͟, with many of these cost saving and therefore dominating the use of formula 375 
milk.  This suggests a clear case for the use of donor milk for all VLBW infants when their mother͛s 376 
milk is unavailable or insufficient to meet an infant͛s needs.  However, insufficient supplies may 377 
mean that rationing is still required.  Comparing the results in Tables 2 and 3 indicates that there is 378 
no optimum allocation scenario across both criteria (maximising lives saved and minimising costs) 379 
and therefore a subjective trade-off between saving lives and saving money would need to be made. 380 
 381 
DISCUSSION 382 
Summary of results 383 
The results reported here suggest that the use of donor milk to reduce the incidence and severity of 384 
NEC in very low birthweight infants would be at least cost-effective, and most likely cost saving, in a 385 
middle-income country such as South Africa.  Following the purchase of donor milk by a neonatal 386 
unit from a milk bank, the savings would be realised to the health service within a short time frame 387 
(i.e. during the infant͛s initial neonatal stay), although the provision of donor milk does require 388 
previous investment in the necessary infrastructure.  389 
 390 
Our results suggest that health outcomes (measured in terms of lives saved) would be maximised by 391 
prioritising the lowest birthweight infants, but that cost savings would be maximised by prioritising 392 
those in the 1,000-1,250g and then the 1,251-1,500g birthweight groups.  These apparently 393 
contradictory results are explained by differences in NEC rates between groups: NEC rates are 394 
highest in the lowest birthweight groups who therefore have the largest headroom for health gains; 395 
but where lives are saved, high healthcare ͞survivorship costs͟ ensue. Therefore those making 396 
allocation decisions may need to make a trade-off between saving lives and saving money. 397 
 398 
Relationship to other studies 399 
Our results confirm previous, but limited, economic evaluations undertaken for developed countries 400 
(Arnold, 2002; Wight, 2001) which also show that the exclusive use of donor milk can be cost-saving. 401 
Replicating economic evaluations in different international contexts is important as results may not 402 
be transferable (Boehler & Lord, 2016).  We have not considered the ethics of rationing in any detail 403 
as others have done (Miracle et al., 2011; Tully, 2002) and some parents or guardians may object to 404 
the use of donor milk (British Association of Perinatal Medicine, 2015). 405 
 406 
Strengths and weaknesses 407 
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We have been explicit about our assumptions, the sources of the data used as parameter values and 408 
incorporated uncertainty in a probabilistic sensitivity analysis, although not for all variables included.  409 
Nevertheless, assumptions are always open to criticism, although we reviewed all of these with a 410 
clinician to ensure that simplifying assumptions did not jeopardise the clinical validity of the model. 411 
We undertook a ͞back of the envelope͟ approach to identifying the potential impact of making 412 
significant changes to these assumptions but did not consider that any such changes would have 413 
signfiicantly changes our conclusions.  Analysis of existing datasets, such as the UK͛s National 414 
Neonatal Research Database, would enable some of these assumptions to be tested, but testing 415 
others may require international collaboration on a prospective register of NEC patients. 416 
 417 
We have also relied on existing datasets to parameterise our model, none of which are themselves 418 
perfect.  For example, the parameter values identified from the literature are not all drawn from 419 
systematic reviews and, in the case of the effect of donor milk on the risk of requiring surgery for 420 
NEC, we have had to extrapolate from data for breast milk in general to donor milk, which may over-421 
estimate the effectiveness of donor milk.  Even though the estimate of the relative risk of NEC was 422 
taken from a systematic review, the authors of the review note weaknesses with the included 423 
studies and the lack of contemporary trials (Quigley & McGuire, 2014).  For both these health 424 
outcomes, the 95% credible intervals from the cohort simulation were fairly wide, suggesting a need 425 
for further primary research to obtain a more precise estimate of the effect of using donor milk.  In 426 
addition, we could not find any data for the effect of donor milk on the risk of NEC by birthweight so 427 
we had to assume the same relative risk across all groups. 428 
 429 
Where we used data from South Africa, we relied on clinical data provided by one hospital and there 430 
may be variation across hospitals even within one country.  Although published data for some 431 
parameters do exist for high income countries (most notably the US), for example the rate of surgical 432 
NEC (Hull et al., 2014), these data are not applicable to many middle-income settings due to the lack 433 
of specialist neonatal equipment such as ventilators.  Our daily neonatal unit costs data were based 434 
on UK data because we were unable to obtain local costs data. Whilst data on South African charges 435 
could be obtained these were not considered a true reflection of the cost of care incurred by the 436 
health service and we therefore needed to estimate South African costs.   437 
 438 
Our model has only considered the short-term effects of donor milk on one neonatal condition (NEC) 439 
and only from the perspective of the health service.  We assumed donors are not paid for their milk; 440 
doing so would reduce the cost-effectiveness of donor milk relative to formula; and also that there 441 
was no wastage of milk. However, even with 25% wastage, total healthcare costs would increase by 442 
less than 1% and therefore incorporating wastage would not affect our conclusions. We did not 443 
include other conditions where donor milk may be beneficial due to a lack of evidence regarding the 444 
effect of donor milk (Meier, Patel, & Esquerra-Zwiers, 2017).  However, survival following NEC may 445 
bring with it future health service costs and challenges for the survivor and their family, which may 446 
be particularly acute in low- and middle-income countries.  We only included one criterion on which 447 
decisions regarding the allocation of donor milk could be made (birthweight), when in reality 448 
decisions may also be affected by maternal desire/intention to breastfeed and an infant͛s prognosis 449 
independent of birthweight.  We only considered the use of donor milk as an exclusive substitute for 450 
formula milk when donor milk is often used to supplement a mother͛s own milk supply while it is 451 
being established (British Association of Perinatal Medicine, 2015). Research to evaluate the 452 
effectiveness of mixed feeding on NEC incidence is required, so this option could also be included in 453 
an economic evaluation. 454 
 455 
Implications for practice  456 
Given the promising cost-effectiveness of donor milk reported here, the allocation decisions 457 
assumed to be required in this paper should not have to be made, because sufficient donor milk 458 
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should be available for all VLBW infants when mother͛s own milk is not available.  The need to 459 
allocate or ration donor milk should therefore be seen as a short-term problem, until the 460 
infrastructure required to ensure a plentiful, consistent and safe supply of donor milk to all neonatal 461 
units can be developed.  Saying that such investment should be made because of the downstream 462 
cost savings that would be generated is all well and good, but funding for healthcare is stretched in 463 
almost all settings so may be challenging to operationalise in practice.   464 
 465 
It is also important to consider the second limiting factor related to the excess demand for donor 466 
milk: a lack of donors.  Recruitment of donors needs to be an on-going process, as there is inevitably 467 
a limit to the time period in which a woman can be a donor.  Work to explore how the number of 468 
donors can be increased – while maintaining the necessary safeguards – would therefore be useful, 469 
bearing in mind that some interventions to increase supply, such as collection from a donor͛s home, 470 
will add to the cost of providing donor milk and therefore reduce its cost-effectiveness.  471 
 472 
Conclusion 473 
Our results have not provided one unique answer to the question of how to allocate donor human 474 
milk between VLBW, because the answer depends on whether the decision-maker prioritises saving 475 
lives or money.  One option is to prioritise saving money in the short-term to use the savings to 476 
invest in the milk banking infrastucture for the long-term; but this solution still raises a number of 477 
ethical and practical considerations.  In addition, our results cannot be considered definitive. We 478 
therefore hope that others will use our model to re-populate it with their own data and update it as 479 
new evidence becomes available. 480 
 481 
KEY MESSAGES 482 
The use of donor human breast milk is a cost-effective alternative to the use of formula milk when a 483 
mother͛s own milk is unavailable or limited in supply. 484 
When the supply of donor milk is limited, lives saved can be maximised by prioritising infants with 485 
the lowest birthweights (<1,000g) and then using additional supplies to give slightly heavier babies 486 
donor milk for 14 days before giving it to the lightest babies for 28 days. Cost savings can be 487 
maximised by prioritising infants with birthweights >1000g. 488 
Decision-makers may have to choose between saving the most lives and saving the most money. 489 
Figure 490 
Figure 1: Example decision tree (1,251-1,500g birthweight group) 491 
Legend: Each block represents one week of time 492 
  493 
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Table 1: Parameter values in basecase and distributions used in the probabilistic sensitivity analysis 594 
 595 
Variable Birthweight 
group/cost type 
Basecase value (95% 
credible interval from 
PSA) 
Probabilistic sensitivity 
analysis (PSA) 
distribution and 
parameter values 
Proportion of infants 500-750g 0.198 (0.191 to 0.205) Dirichlet  
(2,153, 2,491, 2,888, 
3,342) 
751-1,000g 0.229 (0.222 to 0.237) 
1,001-1,250g 0.266 (0.257 to 0.274) 
1,251-1,500g 0.307 (0.299 to 0.316) 
Mean birthweight (g) 500-750g 667 N/A 
751-1,000g 917 
1,001-1,250g 1,167 
1,251-1,500g 1,417 
Feeding duration for 
donor milk (days) 
500-750g 0, 14, 28 N/A 
751-1,000g 0, 14, 28 
1,001-1,250g 0, 14, 28 
1,251-1,500g 0, 14 
Risk of NEC with formula 
milk 
500-750g 0.120 (0.115 to 0.126) Beta (1,568, 11,482) 
751-1,000g 0.092 (0.088 to 0.097) Beta (1,569, 15,454) 
1,001-1,250g 0.057 (0.053 to 0.060) Beta (1,063, 17,731) 
1,251-1,500g 0.033 (0.031 to 0.035) Beta (758, 22,212) 
Relative risk of any NEC 
with donor milk 
 0.360 (0.187 to 0.675) Log normal  
(-1.019, 0.347) 
Relative risk of surgical 
NEC with donor milk 
 0.700 (0.551 to 0.891) Log normal  
(-0.351, 0.124) 
NEC timing, severity and 
mortality 
 See Appendix table 1 N/A 
Non-NEC mortality 500-750g 0.548 N/A 
751-1,000g 0.115 
1,001-1,250g 0.005 
1,251-1,500g 0.019 
Milk costs/ml (2015 USD 
at PPP) 
Formula 0.0529 N/A 
Donor 0.1371 
Milk volumes by 
outcome and 
birthweight group 
 See Appendix table 4 N/A 
Cost of care per day 
(2015 USD at PPP) 
NICU UK: 1,636; SA: 794 N/A 
High care UK: 1,228; SA: 596 
Normal care UK: 681; SA: 330 
Other health care costs 
(2015 USD at PPP) 
Surgery per operation UK: 902; SA: 437 N/A 
Transfer per operation 
each way 
1,162 
Parenteral nutrition 
set-up 
254 
Parenteral nutrition 
per day 
127 
Length of stay and NEC 
costs by outcome and 
birthweight group 
 See Appendix tables 5 & 6 N/A 
Note: For sources and explanations of how distributions for the PSA were derived, please refer to the methods section; SA: 596 
South Africa. 597 
 598 
 599 
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Table 2: Allocating donor milk to maximise the number of lives saved 
 
Donor milk 
availability group (per 
10,000 VLBW infants) 
Optimal allocation scenario 
Mean lives saved 
(95% Credible Interval) 
Probability 
that 
scenario is 
optimal 
BW Group (g): 500-750 710-1,000 
1,001-
1,250 
1,251-
1,500 
    
<5,000L 14 14 0 0 
86 
(45 to 113) 
0.921 
<10,000L 28 14 0 0 
127 
(66 to 168) 
0.996 
<15,000L 28 14 14 0 
162 
(85 to 214) 
0.996 
<20,000L 28 28 14 0 
191 
(100 to 252) 
0.996 
<25,000L 28 28 14 0 
191 
(100 to 252) 
0.614 
<30,000L 28 28 28 0 
200 
(105 to 264) 
0.996 
<35,000L 28 28 14 14 
220 
(115 to 290) 
0.996 
35,000L 28 28 28 14 229 
(119 to 301) 
0.996 
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Table 3: Allocating donor milk to minimise incremental costs 
Donor milk 
availability group 
(per 10,000 VLBW 
infants) 
Optimal allocation scenario (days of donor milk to 
infants in each birthweight group, UK costs) 
Mean 
incremental 
cost (2015 
USD at PPP) 
Probability 
that 
scenario is 
optimal 
Optimal allocation scenario (days of donor milk to 
infants in each birthweight group, South African 
costs) 
Mean 
incremental 
cost (2015 
USD at PPP) 
Probability 
that 
scenario is 
optimal 
BW Group (g): 500-750 710-1,000 
1,001-
1,250 
1,251-
1,500 
    500-750 710-1,000 
1,001-
1,250 
1,251-
1,500 
    
<5,000L 0 14 0 0 298,823 0.899 28 0 0 0 146,098 0.942 
<10,000L 0 0 14 0 -824,987 0.985 0 0 14 0 -182,069 0.958 
<15,000L 0 0 14 0 -824,987 0.980 0 0 14 0 -182,069 0.876 
<20,000L 0 0 14 14 -1,249,641 0.924 0 0 14 0 -182,069 0.793 
<25,000L 0 0 14 14 -1,249,641 0.923 0 0 14 0 -182,069 0.793 
<30,000L 0 0 14 14 -1,249,641 0.883 0 0 14 0 -182,069 0.793 
<35,000L 0 0 14 14 -1,249,641 0.883 0 0 14 0 -182,069 0.793 
35,000L 0 0 14 14 -1,249,641 0.883 0 0 14 0 -182,069 0.793 
Note: negative values represent cost savings.  
 
 
 
 

Appendix table 1: Scenarios included in analysis (days on donor milk given to all infants in each 
birthweight group) 
 
Scenario 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g
Total infants 
fed any 
DM/10,000
1,979 2,292 2,655 3,074
Comparator 0 0 0 0 0 N/A
1 14 0 0 0 1,979           <5,000L
2 28 0 0 0 1,979           <5,000L
3 0 14 0 0 2,292           <5,000L
4 14 14 0 0 4,271           <5,000L
5 28 14 0 0 4,271           <10,000L
6 0 0 14 0 2,655           <10,000L
7 14 0 14 0 4,634           <10,000L
8 0 28 0 0 2,292           <10,000L
9 28 0 14 0 4,634           <10,000L
10 0 0 0 14 3,074           <15,000L
11 14 28 0 0 4,271           <15,000L
12 0 14 14 0 4,947           <15,000L
13 14 0 0 14 5,053           <15,000L
14 14 14 14 0 6,926           <15,000L
15 28 28 0 0 4,271           <15,000L
16 28 0 0 14 5,053           <15,000L
17 28 14 14 0 6,926           <15,000L
18 0 14 0 14 5,366           <15,000L
19 14 14 0 14 7,345           <20,000L
20 0 0 28 0 2,655           <20,000L
21 0 28 14 0 4,947           <20,000L
22 28 14 0 14 7,345           <20,000L
23 14 0 28 0 4,634           <20,000L
24 0 0 14 14 5,729           <20,000L
25 14 28 14 0 6,926           <20,000L
26 14 0 14 14 7,708           <20,000L
27 28 0 28 0 4,634           <20,000L
28 28 28 14 0 6,926           <20,000L
29 0 14 28 0 4,947           <25,000L
30 0 28 0 14 5,366           <25,000L
31 28 0 14 14 7,708           <25,000L
32 14 14 28 0 6,926           <25,000L
33 14 28 0 14 7,345           <25,000L
34 0 14 14 14 8,021           <25,000L
35 14 14 14 14 10,000         <25,000L
36 28 14 28 0 6,926           <25,000L
37 28 28 0 14 7,345           <25,000L
38 28 14 14 14 10,000         <25,000L
39 0 28 28 0 4,947           <30,000L
40 0 0 28 14 5,729           <30,000L
41 14 28 28 0 6,926           <30,000L
42 0 28 14 14 8,021           <30,000L
43 14 0 28 14 7,708           <30,000L
44 14 28 14 14 10,000         <30,000L
45 28 28 28 0 6,926           <30,000L
46 28 0 28 14 7,708           <35,000L
47 28 28 14 14 10,000         <35,000L
48 0 14 28 14 8,021           <35,000L
49 14 14 28 14 10,000         <35,000L
50 28 14 28 14 10,000         <35,000L
51 0 28 28 14 8,021           >=35,000L
52 14 28 28 14 10,000         >=35,000L
53 28 28 28 14 10,000         >=35,000L
Birthweight group DM availability 
group (DM 
available per 
10,000 VLBW 
infants)
Note: The scenarios are ordered in ascending total donor milk volume required.  
Appendix table 2: Distributions of NEC timing, severity and mortality by birthweight group (proportion of NEC cases) 
 
 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 
Timing of onset 
Week 1 0.20 0.30 0.50 0.65 
Week 2 0.30 0.30 0.30 0.35 
Week 3 0.30 0.30 0.15 0 
Week 4 0.20 0.10 0.05 0 
Severity and mortality 
Palliative 0.25 0.25 0 0 
Medical – survive 0.30 0.30 0.40 0.40 
Medical – die 0.30 0.30 0.45 0.45 
Surgical – survive 0.14 0.14 0.14 0.14 
Surgical - die 0.01 0.01 0.01 0.01 
 
 
Appendix table 3: Progression of feeding volumes by birthweight group 
 
 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 
Starting volume 
(ml/kg/day) 
12 12 24 24 
Increase per day 
(ml/kg/day) 
12 24 36 48 
 
  
Appendix table 4: Milk volumes for total hospital stay per infant (ml) by milk type, birthweight group and outcome 
 
 
 
N/A: Based on the data in Appendix Table 2, these outcomes do not occur in the model: no infants >1,000g birthweight acquire palliative NEC and no 
infants >1,250g birthweight acquire NEC after the first two weeks of life. 
 
  
500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 500-750g 751-1,000g 1,001-1,250g 500-750g 751-1,000g 1,001-1,250g
No NEC survive 9,062 8,709 6,738 5,871 840 1,882 2,815 3,605 8,222 6,828 3,923 2,266 3,032 4,964 6,738 6,030 3,745 0
No NEC die 224 539 1,050 1,462 224 539 1,050 1,462 0 0 0 0 224 539 1,050 0 0 0
Medical NEC:
7 days survive 14,787 14,546 12,494 12,013 224 539 1,050 1,462 14,563 14,007 11,443 10,550 224 539 1,050 14,563 14,007 11,443
7 days die 224 539 1,050 1,462 224 539 1,050 1,462 0 0 0 0 224 539 1,050 0 0 0
14 days survive 14,386 14,422 12,392 11,889 840 1,882 2,815 3,605 13,546 12,540 9,577 8,284 840 1,882 2,815 13,546 12,540 9,577
14 days die 840 1,882 2,815 3,605 840 1,882 2,815 3,605 0 0 0 0 840 1,882 2,815 0 0 0
21 days survive 14,228 14,272 12,201 N/A 840 1,882 2,815 N/A 13,388 12,390 9,386 N/A 1,857 3,348 4,681 12,371 10,924 7,520
21 days die 1,857 3,348 4,681 N/A 840 1,882 2,815 N/A 1,017 1,466 1,866 N/A 1,857 3,348 4,681 0 0 0
28 days survive 14,108 14,107 11,991 N/A 840 1,882 2,815 N/A 13,268 12,225 9,176 N/A 3,032 4,964 6,738 11,076 9,142 5,253
28 days die 3,032 4,964 6,738 N/A 840 1,882 2,815 N/A 2,192 3,083 3,923 N/A 3,032 4,964 6,738 0 0 0
Surgical NEC:
7 days survive 21,085 21,076 18,640 18,343 224 539 1,050 1,462 20,861 20,537 17,590 16,880 224 539 1,050 20,861 20,537 17,590
7 days die 224 539 1,050 1,462 224 539 1,050 1,462 0 0 0 0 224 539 1,050 0 0 0
14 days survive 20,406 20,637 18,138 17,732 840 1,882 2,815 3,605 19,566 18,755 15,323 14,127 840 1,882 2,815 19,566 18,755 15,323
14 days die 840 1,882 2,815 3,605 840 1,882 2,815 3,605 0 0 0 0 840 1,882 2,815 0 0 0
21 days survive 19,996 20,140 17,505 N/A 840 1,882 2,815 N/A 19,156 18,258 14,690 N/A 1,857 3,348 4,681 18,139 16,792 12,824
21 days die 1,857 3,348 4,681 N/A 840 1,882 2,815 N/A 1,017 1,466 1,866 N/A 1,857 3,348 4,681 0 0 0
28 days survive 19,597 19,592 16,808 N/A 840 1,882 2,815 N/A 18,757 17,710 13,993 N/A 3,032 4,964 6,738 16,565 14,628 10,070
28 days die 3,032 4,964 6,738 N/A 840 1,882 2,815 N/A 2,192 3,083 3,923 N/A 3,032 4,964 6,738 0 0 0
Palliative NEC:
7 days 224 539 N/A N/A 224 539 N/A N/A 0 0 N/A N/A 224 539 N/A 0 0 N/A
14 days 840 1,882 N/A N/A 840 1,882 N/A N/A 0 0 N/A N/A 840 1,882 N/A 0 0 N/A
21 days 1,857 3,348 N/A N/A 840 1,882 N/A N/A 1,017 1,466 N/A N/A 1,857 3,348 N/A 0 0 N/A
28 days 3,032 4,964 N/A N/A 840 1,882 N/A N/A 2,192 3,083 N/A N/A 3,032 4,964 N/A 0 0 N/A
Feeding volume, all formula milk Feeding volume, up to 14 days donor milk Feeding volume, up to 28 days donor milk
Volume of donor milk Volume of formula milk Volume of donor milk Volume of formula milk
Appendix table 5: Length of stay (LOS) in days by type of care by outcome and birthweight group 
 
 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 
No NEC – survive (total LOS) 
NICU 21 21 7 7 
High care 21 14 7 7 
Normal care 14 7 14 7 
No NEC – die (total LOS) 
NICU 7 7 7 7 
Palliative NEC (LOS following NEC diagnosis) 
NICU 2 2 N/A N/A 
Medical NEC - survive (additional LOS) 
NICU 7 7 7 7 
High care 7 7 7 7 
Normal care 7 7 7 7 
Medical NEC – die (LOS following NEC diagnosis) 
NICU 7 7 7 7 
Surgical NEC – survive (additional LOS) 
NICU 21 21 21 21 
High care 14 14 14 14 
Normal care 7 7 7 7 
Surgical NEC – die (LOS following NEC diagnosis) 
NICU 21 21 21 21 
 NICU: Neonatal intensive care unit 
  
Appendix table 6: Length of stay (days) by level of care, birthweight group and outcome and mean incremental cost of NEC 
 
 
 
N/A: Based on the data in Appendix Table 2, these outcomes do not occur in the model: no infants >1,000g birthweight acquire palliative NEC and no 
infants >1,250g birthweight acquire NEC after the first two weeks of life. 
TPN: Total parenteral nutrition. 
 
 
500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g 500-750g 751-1,000g 1,001-1,250g 1,251-1,500g
No NEC survive 21 21 7 7 21 14 7 7 14 7 14 7 N/A N/A N/A N/A
No NEC die 7 7 7 7 0 0 0 0 0 0 0 0 N/A N/A N/A N/A
Medical NEC:
All survivors:
7 days survive 28 28 14 14 28 21 14 14 21 14 21 14
7 days die 14 14 14 14 0 0 0 0 0 0 0 0 45,633-         32,272-         5,529-           765-              
14 days survive 28 28 14 14 28 21 14 14 21 14 21 14
14 days die 21 21 14 14 0 0 7 7 0 0 0 0 34,178-         20,817-         3,068           7,832           
21 days survive 28 28 14 N/A 28 21 14 N/A 21 14 21 N/A
21 days die 28 28 14 N/A 0 0 7 N/A 0 0 7 N/A 22,723-         9,361-           7,832           12,597         
28 days survive 28 28 14 N/A 28 21 14 N/A 21 14 21 N/A
28 days die 28 28 14 N/A 7 7 7 N/A 0 0 14 N/A 14,126-         765-              12,597         1,141           
Surgical NEC:
All survivors:
7 days survive 42 42 28 28 35 28 21 21 21 14 21 14
7 days die 28 28 28 28 0 0 0 0 0 0 0 0 18,186-         4,825-           21,918         26,683         
14 days survive 42 42 28 28 35 28 21 21 21 14 21 14
14 days die 35 35 28 28 0 0 7 7 0 0 0 0 6,731-           6,631           30,515         35,280         
21 days survive 42 42 28 N/A 35 28 21 N/A 21 14 21 N/A
21 days die 42 42 28 N/A 0 0 7 N/A 0 0 7 N/A 4,725           18,086         35,280         40,044         
28 days survive 42 42 28 N/A 35 28 21 N/A 21 14 21 N/A
28 days die 42 42 28 N/A 7 7 7 N/A 0 0 14 N/A 13,322         26,683         40,044         5,678           
Palliative NEC:
7 days 9 9 N/A N/A 0 0 N/A N/A 0 0 N/A N/A 54,450-         41,089-         N/A N/A
14 days 16 16 N/A N/A 0 0 N/A N/A 0 0 N/A N/A 42,994-         29,633-         N/A N/A
21 days 23 23 N/A N/A 0 0 N/A N/A 0 0 N/A N/A 31,539-         18,178-         N/A N/A
28 days 23 23 N/A N/A 7 7 N/A N/A 0 0 N/A N/A 22,942-         9,581-           N/A N/A
25,958
67,524
NICU days High care days Normal care days
Mean incremental cost of NEC per infant, 2015 USD at 
PPP (including TPN but excluding milk costs) 
Comparator: No NEC survive
